Zydus Gets Final USFDA Nod for Carbidopa Tablets | CORPORATE ETHOS

Zydus Gets Final USFDA Nod for Carbidopa Tablets

By: | May 10, 2018
Zydus-Cadila

May 10: Drug manufacturing major Zydus Cadila on Thursday said that it has received the final approval from the USFDA to market its Carbidopa Tablets, 25 mg.

According to the company, the product is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson’s disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The group now has more than 190 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare, the group’s listed entity, were trading at Rs 403.40, up 0.72% from the previous closing of Rs 405.50, on BSE at 9.59 am today.